Valeant, Croma to expand Bausch & Lomb portfolio

An agreement between Valeant and Croma may provide additional ophthalmic opportunities for Bausch & Lomb’s United States market, according to a Bausch & Lomb press release.

Valeant recently acquired hundreds of ophthalmic products from Croma. Under this agreement, Valeant will distribute Croma’s ophthalmology and orthopedics products in Western Europe. Because Croma’s products are not yet available in the United States, Valeant will apply for regulatory approval, according to the release.

 “Our agreement with Croma gives us access to a rich basket of products on the European market today, as well as others currently in development,” said Dr. Ari Kellen, head of U.S. eye health for Bausch & Lomb. “This access is part of our ongoing strategy to grow our ophthalmic business and meet the needs of our U.S. customers.”